EP1309346A4 - Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists - Google Patents

Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists

Info

Publication number
EP1309346A4
EP1309346A4 EP01962087A EP01962087A EP1309346A4 EP 1309346 A4 EP1309346 A4 EP 1309346A4 EP 01962087 A EP01962087 A EP 01962087A EP 01962087 A EP01962087 A EP 01962087A EP 1309346 A4 EP1309346 A4 EP 1309346A4
Authority
EP
European Patent Office
Prior art keywords
hiv
infection
treatment
receptor antagonists
inflammatory disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01962087A
Other languages
German (de)
French (fr)
Other versions
EP1309346A2 (en
Inventor
Barbara A Sherry
Michael I Bukrinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Picower Institute for Medical Research
Original Assignee
Picower Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Picower Institute for Medical Research filed Critical Picower Institute for Medical Research
Publication of EP1309346A2 publication Critical patent/EP1309346A2/en
Publication of EP1309346A4 publication Critical patent/EP1309346A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP01962087A 2000-08-10 2001-08-10 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists Withdrawn EP1309346A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63703300A 2000-08-10 2000-08-10
US637033 2000-08-10
PCT/US2001/025178 WO2002013763A2 (en) 2000-08-10 2001-08-10 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists

Publications (2)

Publication Number Publication Date
EP1309346A2 EP1309346A2 (en) 2003-05-14
EP1309346A4 true EP1309346A4 (en) 2005-06-01

Family

ID=24554263

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01962087A Withdrawn EP1309346A4 (en) 2000-08-10 2001-08-10 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists

Country Status (6)

Country Link
EP (1) EP1309346A4 (en)
JP (1) JP2004505997A (en)
AU (1) AU2001283295A1 (en)
CA (1) CA2418303A1 (en)
IL (1) IL154358A0 (en)
WO (1) WO2002013763A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1442203A (en) * 2003-05-15 2003-09-17 陈志南 SARS crown virus and AIDS virus (HIV-1)-CD 147 acceptor target antagonist
EP1732599A4 (en) * 2004-03-25 2008-05-14 Centocor Inc Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis
EP1771465B1 (en) * 2004-07-23 2012-07-11 GE Healthcare UK Limited Cell cycle reporting cell line
JP4911950B2 (en) * 2005-11-07 2012-04-04 晃 伊東 Cancer invasion / metastasis inhibitor using partial peptide of MMP-1
US8007808B2 (en) * 2008-04-04 2011-08-30 The Board Of Trustees Of The Univeristy Of Illinois Composition and method for facilitating the internalization of a therapeutic agent into a cell
US20110287008A1 (en) * 2008-05-23 2011-11-24 Uti Limited Partnership Inhibition of emmprin to treat multiple sclerosis
US8338171B2 (en) * 2009-08-31 2012-12-25 Centocor Ortho Biotech Inc. Baboon homolog of human CD147
EP2877492A1 (en) * 2012-07-27 2015-06-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US10365280B2 (en) * 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
CN111420048B (en) * 2020-03-11 2023-09-19 中国人民解放军第四军医大学 Application of anti-BASIGAN humanized antibody in preparation of medicine for treating novel coronavirus pneumonia
CN117187190A (en) * 2023-11-07 2023-12-08 深圳湾实验室 Anti-cyclophilin A monoclonal antibody and application thereof in treatment of rheumatoid arthritis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840305A (en) * 1996-03-14 1998-11-24 The Picower Institute For Medical Research Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity
WO1999045031A2 (en) * 1998-03-03 1999-09-10 Abgenix, Inc. Cd147 binding molecules as therapeutics

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840305A (en) * 1996-03-14 1998-11-24 The Picower Institute For Medical Research Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity
WO1999045031A2 (en) * 1998-03-03 1999-09-10 Abgenix, Inc. Cd147 binding molecules as therapeutics

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIRSCH A H ET AL: "The pattern of expression of CD147/neurothelin during human T-cell ontogeny as defined by the monoclonal antibody 8D6.", TISSUE ANTIGENS. AUG 1997, vol. 50, no. 2, August 1997 (1997-08-01), pages 147 - 152, XP009041532, ISSN: 0001-2815 *
PUSHKARSKY TATIANA ET AL: "CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 11, 22 May 2001 (2001-05-22), pages 6360 - 6365, XP002310597, ISSN: 0027-8424 *
SHERRY BARBARA ET AL: "Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 95, no. 4, 17 February 1998 (1998-02-17), pages 1758 - 1763, XP002310598, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
CA2418303A1 (en) 2002-02-21
WO2002013763A2 (en) 2002-02-21
IL154358A0 (en) 2003-09-17
AU2001283295A1 (en) 2002-02-25
EP1309346A2 (en) 2003-05-14
WO2002013763A3 (en) 2002-08-15
JP2004505997A (en) 2004-02-26

Similar Documents

Publication Publication Date Title
IL153708A0 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
NO20022974D0 (en) Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
HUP0301020A3 (en) Early diagnosis of conformational diseases
MXPA03000923A (en) Carboxamide compounds and their use as antagonists of a human 11cby receptor.
NO20042208L (en) Vaginally administered anti-dysrhythmic agents for the treatment of pelvic pain
IL154358A0 (en) Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
PT1230230E (en) DERIVATIVES OF INDENO-DI-HYDROTIAZOLE AND ITS PREPARATION AND ITS USE AS ANOREXIGENIC MEDICINES
EE05127B1 (en) A kit of parts and a pharmaceutical preparation containing a P2T receptor antagonist or a pharmaceutically acceptable derivative thereof and an antithrombotic agent and their use in medicine
EP1154997A4 (en) Pharmaceutically active compounds and methods of use thereof
GB0023915D0 (en) Treatment of neuroinflammatory disease
EE200200185A (en) Synergistic combinations of NK1 receptor antagonist and GABA structural analog
GB9909392D0 (en) Treatment, imaging and diagnosis of disease
IL151019A0 (en) Microcompetition and human disease
EP1308509A4 (en) Novel physiologically active peptide and use thereof
EP1322778A4 (en) Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
HUP0203181A3 (en) Peptides for treatment of erectile dysfunction, pharmaceutical compositions and their use
WO2002009762A3 (en) Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection
IL153921A0 (en) Use of il-8 receptor antagonists in the treatment of virus infections
HK1044022A1 (en) In vivo treatment of joint disease using interleukin-1 receptor antagonists
GB0019096D0 (en) Biologically and therapeutically active agents against HIV-1
GB0119244D0 (en) Biologically and therapeutically active agents against HIV-1
AU2002350212A8 (en) Pharmaceutically active compounds and methods of use thereof
GB9914444D0 (en) Biologically and therapeutically active agents against HIV-1
GB0218483D0 (en) Biologically and therapeutically active agents against HIV-1
ATE285468T1 (en) TISSUE TREATMENT PREPARATION

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030310

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 9/90 B

Ipc: 7C 07K 14/705 B

Ipc: 7C 07K 16/28 B

Ipc: 7A 61K 39/395 A

A4 Supplementary search report drawn up and despatched

Effective date: 20050408

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050707